Abstract: A prosthetic device includes a polymer lattice structure. The lattice structure includes a first surface arranged to face toward a residual limb, a second surface arranged to face away from the residual limb, a thickness between the first and second surfaces, and a variable lattice density across the thickness.

Abstract: A towel mat comprising a fabric panel having a top, a bottom, a first end, a second end, a first side, and a second side, wherein the ends are shorter than the sides. A top pocket having a padded lining, the pocket coupled to the top of the fabric panel near the first end and extending to a predetermined shape when the pocket is filled. The pocket is inflatable and shaped to support a user in a position that is at least partially upright. The bottom of the panel comprises a waterproof barrier layer. The towel mat further comprising a weighted portion sewn to the panel. The panel has at least one corner, and wherein the weighted portion comprises a compartment in which a user may place a weighted material.

Abstract: A prosthetic device includes a polymer lattice structure. The lattice structure includes a first surface arranged to face toward a residual limb, a second surface arranged to face away from the residual limb, a thickness between the first and second surfaces, and a variable lattice density across the thickness.

Abstract: A prosthetic device includes a polymer lattice structure. The lattice structure includes a first surface arranged to face toward a residual limb, a second surface arranged to face away from the residual limb, a thickness between the first and second surfaces, and a variable lattice density across the thickness.

Abstract: The present invention relates to interferon-gamma (IFN-?) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-? production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof.

Abstract: A centrifugal fan rotor having a frame with a rotary axis and a plurality of blades on the frame at circumferentially spaced locations around the rotary axis. The plurality of blades each has a leading edge and a trailing edge radially outside of the leading edge. The plurality of blades each has circumferentially oppositely facing first and second surfaces each extending between respective leading and trailing edges. The plurality of blades each has a material bonded at the leading edge and over only a portion of the exposed surface area of one of the first and second surfaces.

Abstract: A method of forming a layered candle assembly includes positioning a candle core in a form. A layer of powdered wax is loaded into the form. The powdered wax layer has an outer region and an inner region. Mechanical force is applied to compress the outer region of the powdered wax layer and form an upper interface surface that is substantially non-horizontal. The outer perimeter of the interface surface is visible to an observer in the finished candle assembly. A liquefied fuel substance is poured over the top of the powdered wax layer to form a layer of solid wax. A wick may be added to at a desirable stage in the method of forming the layered candle assembly. The powdered wax and solid wax layers may each have a color or a combination of colors and/or a scent component or a combination of scent components.

Abstract: An extension assembly for a processed crop storage tank on a combine. A closure assembly for a top opening on the tank has at least one panel with one surface area that is exposed to bound a part of an exterior space above the storage space with the closure assembly open. The extension assembly has a first extension panel with a first surface with a first area and a connecting system through which the first extension panel is operatively connected to the combine. The first extension panel is changeable between a deployed position and a stored position. In the deployed position the first surface and one surface define a combined exposed surface area that is greater than the first area of the first surface. The combined surface area is exposed to confine processed crop in the exterior space with the closure assembly open.

Abstract: The present invention relates to interferon-gamma (IFN-?) inhibitors, and their utility in treating or controlling diseases that can be treated or controlled through inhibition of IFN-? production, such as Alzheimer's disease, prion diseases, multiple sclerosis, epilepsy, rheumatoid arthritis, inflammatory bowel disease, uveitis, autoimmune skin diseases, psoriasis, Sjögren's syndrome, Crohn's disease, and type 1 diabetes mellitus. The compounds are of Formula 1, 2 3, or are solvates, tautomers, or pharmaceutically acceptable salts thereof.

Abstract: A centrifugal fan rotor having a frame with a rotary axis and a plurality of blades on the frame at circumferentially spaced locations around the rotary axis. The plurality of blades each has a leading edge and a trailing edge radially outside of the leading edge. The plurality of blades each has circumferentially oppositely facing first and second surfaces each extending between respective leading and trailing edges. The plurality of blades each has a material bonded at the leading edge and over only a portion of the exposed surface area of one of the first and second surfaces.

Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: A harvesting unit with a combine, having a user cab. A harvesting apparatus, advanced by the combine, has a frame and a harvesting assembly on the frame configured to process severed crop over a width between spaced sides of the frame. A fluid delivery system discharges pressurized fluid in discrete streams each directed to at least one of: a) facilitate severance of crop by the harvesting assembly; and b) facilitate advancement of severed crop rearwardly in relationship to the frame for further processing. A user can selectively vary at least one of: a) a volume of pressurized fluid; and b) a direction of pressurized fluid in the discrete streams. A control system has at least one actuator accessible and operable from outside of the cab through a user input to cause the at least one of the volume of pressurized fluid discharged, and direction of the pressurized fluid, in the discrete streams to be varied.

Abstract: A harvesting unit with a combine, having a user cab. A harvesting apparatus, advanced by the combine, has a frame and a harvesting assembly on the frame configured to process severed crop over a width between spaced sides of the frame. A fluid delivery system discharges pressurized fluid in discrete streams each directed to at least one of: a) facilitate severance of crop by the harvesting assembly; and b) facilitate advancement of severed crop rearwardly in relationship to the frame for further processing. A user can selectively vary at least one of: a) a volume of pressurized fluid; and b) a direction of pressurized fluid in the discrete streams. A control system has at least one actuator accessible and operable from outside of the cab through a user input to cause the at least one of the volume of pressurized fluid discharged, and direction of the pressurized fluid, in the discrete streams to be varied.

Abstract: An extension assembly for a processed crop storage tank on a combine. A closure assembly for a top opening on the tank has at least one panel with one surface area that is exposed to bound a part of an exterior space above the storage space with the closure assembly open. The extension assembly has a first extension panel with a first surface with a first area and a connecting system through which the first extension panel is operatively connected to the combine. The first extension panel is changeable between a deployed position and a stored position. In the deployed position the first surface and one surface define a combined exposed surface area that is greater than the first area of the first surface. The combined surface area is exposed to confine processed crop in the exterior space with the closure assembly open.

Abstract: A method of forming a layered candle assembly includes positioning a candle core in a form. A layer of powdered wax is loaded into the form. The powdered wax layer has an outer region and an inner region. Mechanical force is applied to compress the outer region of the powdered wax layer and form an upper interface surface that is substantially non-horizontal. The outer perimeter of the interface surface is visible to an observer in the finished candle assembly. A liquefied fuel substance is poured over the top of the powdered wax layer to form a layer of solid wax. A wick may be added to at a desirable stage in the method of forming the layered candle assembly. The powdered wax and solid wax layers may each have a color or a combination of colors and/or a scent component or a combination of scent components.

Abstract: A method of forming a layered candle assembly includes positioning a candle core in a form. A layer of powdered wax is loaded into the form. The powdered wax layer has an outer region and an inner region. Mechanical force is applied to compress the outer region of the powdered wax layer and form an upper interface surface that is substantially non-horizontal. The outer perimeter of the interface surface is visible to an observer in the finished candle assembly. A liquefied fuel substance is poured over the top of the powdered wax layer to form a layer of solid wax. A wick may be added to at a desirable stage in the method of forming the layered candle assembly. The powdered wax and solid wax layers may each have a color or a combination of colors and/or a scent component or a combination of scent components.

Abstract: A method of treating a disorder. The method includes administering to a subject in need thereof a compound of general formula (I): Each of A, N*, X, Y, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: A method of treating a disorder such as epilepsy, multiple sclerosis, glaucoma and uveitis, cerebral traumas and cerebral ischaemias, stroke, head injury, spinal cord injury, surgical trauma, neurodegenerative disorders, motorneurone disease, Alzheimer's disease, Parkinson's disease, chronic inflammatory pain, neuropathic pain, migraine, bipolar disorder, mood, anxiety and cognitive disorders, schizophrenia, or trigeminal autonomic cephalalgias. The method includes administering to a subject in need thereof substituted 1,2,4-triazine compounds of formula (I): Each of A, N*, X, Y, Z, R1, and R2 is defined herein. Also disclosed are compounds of the formula and a pharmaceutical composition containing such a compound.

Abstract: Provided herein are compositions and methods for eliciting an immune response against Porphyromonas gingivalis. The compositions and methods relate to P. gingivalis polypeptides and fragments and variants thereof and the corresponding polynucleotides which are useful in the diagnosis, prevention and therapy of P. gingivalis infections (e.g. periodontitis). Antibodies against the polypeptides and compositions and methods including these antibodies are also disclosed. The disclosure also describes methods for the detection, prevention and treatment of P. gingivalis infection (e.g. periodontitis).

Abstract: The present invention relates to triazine compounds having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. The compounds are of formula I: in which R1 is a halo-alkyl group and A is an optionally substituted aromatic heterocyclic or carbocyclic ring system, or a pharmaceutically acceptable salt or solvate thereof.